Trinity Innovation Bioventure Singapore

What Trinity Innovation Bioventure Singapore does

Trinity Innovation Bioventure Singapore Pte. Ltd. (TIBS) is a licensed biomed venture capital fund established in 2018 as part of the Trinity Innovation Fund group, headquartered at Singapore Science Park 1. The firm operates under a "Two organizations, One Team" model with its China-affiliated parent Trinity Innovation Fund (TIF), giving it cross-border deal flow between Singapore's academic innovation ecosystem and the Chinese biotech market. Its stated investment thesis is "In Asia, for Global," focused on early-stage biotech companies with breakthrough platform technologies addressing unmet medical needs.

TIBS's core activities are equity investment in seed, Series A, and follow-on rounds alongside hands-on project incubation — including project management by the investment team and management team recruitment — for portfolio companies spun out of academic and research institutions. The firm has invested in over a dozen biotech companies across therapeutic areas including RNAi therapeutics (Argo Biopharma, Ribo), ADCs and bispecific antibodies (VelaVigo, AxCynsis), small molecules (Dizal Pharmaceutical, TransThera Sciences), epigenetics (Epigenic Therapeutics), metabolic disease (Cholesgen), cardiovascular (Brano Therapeutics), and antibody discovery (HiFiBiO Therapeutics). Notable portfolio milestones include Argo Biopharma's ~$4.165B Novartis licensing deal, VelaVigo's combined ~$1.24B out-licensing transactions, Ribo's $2B+ Boehringer Ingelheim partnership, TransThera Sciences' Hong Kong Stock Exchange listing (02617.HK) and Hang Seng Index inclusion, and Dizal Pharmaceutical's NMPA approval of Sunvozertinib.

TIBS generates returns through capital appreciation on portfolio company equity, realized via IPOs, M&A, licensing deal proceeds, and secondary sales; fund-level fees are not publicly disclosed. The fund is led by Founding Partner Jack Yin Zheng, supported by Partner David Wang Xukun, Scientific Advisor Dr. Thomas Keller (ex-Novartis), Investment Partner Ivan Cao, Managing Director Langdon Wu, and Managing Director Taoqi Huangfu. Strategic ecosystem partnerships with the National Health Innovation Centre Singapore (NHIC), SGInnovate, and Duke-NUS Medical School's LIVE Ventures provide structured access to Singapore-origin academic spin-offs.

Name

Trinity Innovation Bioventure Singapore

Legal name

Trinity Innovation Bioventure Singapore Pte. Ltd.

Website

https://trinity-fund.com.sg

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

TIBS is a Singapore-licensed biomed venture capital fund (founded 2018) that invests in and incubates early-stage Asian biotech startups with breakthrough platform technologies, leveraging a cross-border synergy with Trinity Innovation Fund to access both Singapore academic spin-offs and China-based biotech opportunities.

Ownership category

akta.pro rank

Product category

Venture Capital / Biomedical Investment

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Debt Providers (FSANAAAL)

Keywords

• Biomed venture capital
• Early-stage biotech investment
• Biomedical innovation funding
• Biotech incubation services
• Healthcare investment

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Venture Capital Fund Management: TIBS generates returns through equity investments in early-stage biotech companies. The fund participates in financing rounds (seed, Series A, and follow-on investments) and realizes returns through portfolio company exits via IPO, M&A, or secondary sales. TIBS provides capital to spin-offs from academic institutions and research centers, targeting companies with breakthrough platform technologies and differentiated scientific merit.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

TIBS is a licensed biomed venture capital fund that invests equity capital into early-stage biotechnology companies with breakthrough platform technologies targeting unmet medical needs. The fund also provides project incubation services, including hands-on project management by its investment team to grow asset value, management team recruitment, and strategic resources to accelerate portfolio company development across Asia.

Product overview

Trinity Innovation Bioventure Singapore operates as a licensed biomed venture capital fund that offers two integrated service offerings: venture capital investment services for biomedical innovations and project incubation services for early-stage biotech companies. The investment services focus on identifying and funding biotech companies with breakthrough platform technologies targeting global unmet medical needs, while the incubation services provide hands-on project management, team recruitment, and strategic resources to maximize asset value. The company also maintains strategic partnerships with academic institutions and government agencies in Singapore to access and develop innovative health-tech solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Biomed Venture Capital Investment Services

Quantifiable outcome

• TIBS portfolio companies have generated multiple major licensing transactions exceeding billions of dollars in total potential value
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core.

• LIVE Ventures (Duke-NUS Medical School)coreStrategic or Co-development Partner · 6 May 2026LIVE Ventures is Duke-NUS Medical School's early-stage innovation fund and incubation programme. TIBS partnered with LIVE Ventures on the Brano Therapeutics investment, marking LIVE Ventures' first direct investment in a spin-off company and TIBS's second partnership with a Singapore academic institution. LIVE Ventures provides scientific expertise, research platforms, and datasets to accelerate therapeutic development.
• National Health Innovation Centre Singapore (NHIC)coreStrategic or Co-development Partner · 17 October 2022TIBS partnered with NHIC on October 17, 2022, to co-create biotech start-ups arising from home-grown, cost-effective technologies. TIBS collaborates with NHIC to enhance its capability of turning locally developed cutting-edge biotechnologies into innovative therapeutics. The CADRE2 collaboration combines the strengths of public and private sectors: NHIC identifies and supports healthcare objectives while TIBS introduces commercial discipline to prepare projects for market readiness and investment.
• Dr. Thomas KellercoreOthers · 20 April 2022Dr. Thomas Keller, former Head of Chemistry at Novartis Respiratory Research Center and multiple Novartis research institutes, joined TIBS as Investment Partner on January 1, 2022. He brings over 25 years of experience in drug discovery and industrial drug discovery research group setup, with compounds advanced into clinical and commercial stages.
• Dr. Taoqi HuangfucoreOthers · 20 April 2022Dr. Taoqi Huangfu joined TIBS as Managing Director on February 1, 2022, bringing experience in biomedical R&D, market authorization, and operation management. Previously served in Singapore Public Service as Section Head and Deputy Director, and worked with biotechnology companies including Blueprint Asia and SingVax.
• Langdon WucoreOthers · 20 April 2022Langdon Wu joined TIBS as General Manager on January 1, 2022, bringing over 20 years of leadership experience at Thomson Reuters, LEGO Group, P&G, and Accenture. Responsible for overall fund operations, with expertise in contracting, partnership management, commercial management, and compliance.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• OrbiMed: Global healthcare-dedicated investment firm with significant Asia presence, having co-invested with TIBS in Epigenic Therapeutics. Directly comparable as a healthcare-specialized investor with both growth and venture strategies in biotech.
• Qiming Venture Partners: China-focused VC firm with one of the largest dedicated healthcare practices in Asia, having co-led investments alongside TIBS in companies like Epigenic Therapeutics. Directly comparable as a healthcare-focused VC manager pursuing early-stage biotech opportunities in Asia.
• Loyal Valley Capital: Asia-focused alternative asset manager with a dedicated healthcare/biotech strategy. Comparable to TIBS as a healthcare-specialized investor targeting innovation-driven opportunities in Chinese and Asian biotech markets.
• Highlight Capital: Healthcare-focused investment firm in Greater China region with both venture and growth strategies. Directly comparable to TIBS in pursuing biomedical investments with a China-Asia focus and global commercialization angle.
• 6 Dimensions Capital: Healthcare-dedicated investment firm combining venture and growth capital across Asia. Directly comparable to TIBS in targeting early-to-growth-stage biomedical companies with cross-border value creation strategies.

Emerging players

• Boehringer Ingelheim Venture Fund: Corporate venture arm of Boehringer Ingelheim making equity investments in early-stage biotech. Comparable as a strategic biotech investor that has partnered with TIBS portfolio companies (Ribo Life Science) and pursues breakthrough therapeutics development.
• ARCH Venture Partners: US-based early-stage biotech venture firm with focus on breakthrough platform technologies. Comparable as a science-driven VC pursuing transformative biomedical opportunities, though primarily US-focused with different geographic exposure.

Broad incumbents

• Hillhouse Investment: Major Asia-focused investment firm with significant healthcare/biotech allocation through HHLR and dedicated healthcare vehicles. Comparable as a much larger incumbent operating broadly across healthcare while also competing for the same biotech deals.
• Legend Capital: Established China-focused VC and growth investor with dedicated healthcare practice. Comparable as a broad incumbent with longer operating history than TIBS but overlapping investment focus on early-stage biomedical opportunities.
• Sequoia Capital China (HongShan): One of the largest venture and growth investors in China with broad sector coverage including healthcare. Comparable as a broad incumbent participating in some of TIBS's portfolio rounds (e.g., Vibrant Therapeutics) while competing for top biotech deals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/trinity-innovation-bioventure-singapore

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trinity Innovation Bioventure Singapore